In re Application of: Hancock, et al.

Application No.: 10/661,471

Filed: September 12, 2003

Page 2

PATENT ATTY. DOCKET NO.: UBC1180-2

AMENDMENT

Amendments to the Specification:

Following the abstract, please insert the attached Sequence Listing with subsequent page numbering thereafter.

Please replace paragraph [0182] with the following amended paragraph:

[0182] Total RNA from two independent experiments was isolated from 16HBE40- cells using RNaqueous (Ambion) as described by the manufacturer. The samples were DNase treated, and then cDNA synthesis was accomplished by using a first-strand cDNA synthesis kit (Gibco). The resultant cDNAs were used as a template in PCRs for various cytokine genes MCP-1 (5'-TCATAGCAGCCACCTTCATTC-3' (SEQ ID NO:59), 5'-

TAGCGCAGATTCTTGGGTTG-3 (SEQ ID NO:60)), MCP-3, (5'-

TGTCCTTTCTCAGAGTGGTTCT-3' (SEQ ID NO:61), 5'-

TGCTTCCATAGGGACATCATA-3' (SEQ ID NO:62)) IL-6, (5'-

ACCTGAACCTTCCAAAGATGG-3' (SEQ ID NO:63), 5'-

GCGCAGAATGAGATGAGTTG-3' (SEQ ID NO:64), and IL-8,(5'-

GTGCAGAGGGTTGTGGAGAAG-3' (SEQ ID NO:65), 5'-

TTCTCCCGTGCAATATCTAGG-3' (SEQ ID NO:66))Each RT-PCR reaction was performed in at least duplicate. Results were analysed in the linear phase of amplification and normalized to the housekeeping control, glyceraldehyde-3-phosphate dehydrogenase. Reactions were verified for RNA amplification by including controls without reverse transcriptase.